Richard Jäger obtained his Ph.D. degree in 1997, working on the role of Bcl-2 in breast cancer in a transgenic model. He finished his postdoctoral training on mammary gland biology at the Tiefenau Laboratories, Department of Clinical Research, University of Berne, Switzerland. Then, Jäger joined Hubert Schorle’s Group, first at the Institute for Toxicology and Genetics in Karlsruhe, then at the University of Bonn Medical School in Bonn, Germany, to conduct research on AP-2 transcription factors and apoptosis in mammary development and breast cancer using transgenic technology. In 2009, he joined the National University of Ireland, Galway, Ireland, where he worked on apoptosis and endoplasmic reticulum stress in breast cancer. Currently, Jäger works as a Professor of Biology at the University of Applied Sciences Bonn-Rhein-Sieg, Germany.
Biography Updated on 4 July 2012